Phio Pharmaceuticals Corp. Common Stock (PHIO) is a publicly traded Healthcare sector company. As of November 5, 2026, PHIO trades at $0.81 with a market cap of $10.11M and a P/E ratio of -0.68. PHIO moved -4.86% today. Year to date, PHIO is -31.20%; over the trailing twelve months it is -49.05%. Its 52-week range spans $0.77 to $4.19. Analyst consensus is buy with an average price target of $14.00. Rallies surfaces PHIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Phio Pharmaceuticals Q3 net loss widens 74% to $4.16 million: Phio Pharmaceuticals’ third-quarter 2026 net loss widened 74% year over year to $4.16 million, while research and development spending more than doubled to $3.06 million. Cash and cash equivalents were $10.61 million at September 30, 2026.
| Metric | Value |
|---|---|
| Price | $0.81 |
| Market Cap | $10.11M |
| P/E Ratio | -0.68 |
| EPS | $-1.45 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.19 |
| 52-Week Low | $0.77 |
| Volume | 115.72K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-8.70M |
| Gross Margin | 0.00% |
1 analysts cover PHIO: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.00.